Efficacy of sodium glucose cotransporter 2 inhibitors for heart failure with preserved and mildly reduced ejection fraction: a systematic review and meta-analysis

28 August 2022 (15:15 - 16:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Kathleen Rivera

Philippine Heart Center, Manila (Philippines)

6 More presentations in this session

Presentation thumbnail

Adherence and discontinuation of optimal heart failure therapies according to age

Miss C. Garred (Herlev, DK)

Abstract Slides

Presentation thumbnail

Maximally tolerated guideline-directed medical therapy and barriers to optimization in patients with heart failure with reduced ejection fraction: The COAPT trial

Associate Professor Z. Cox (Nashville, US)

Abstract Slides

Presentation thumbnail

Real-world eligibility for vericiguat according to trial, guideline, and labelling eligibility criteria: data from the Swedish Heart Failure Registry

Mr V. Nguyen (Stockholm, SE)

Abstract Slides

Presentation thumbnail

Compliance to guideline-recommended pharmacotherapy in patients with heart failure, 2014 to 2020

Doctor K. Odegaard (Oslo, NO)

Abstract Slides

Presentation thumbnail

Comparative efficacy of novel drugs as an addition to guideline-directed medical therapy for heart failure with reduced ejection fraction: a network meta-analysis of randomised controlled trials

Mr T. Suebsaicharoen (Bangkok, TH)

Abstract Slides

Access the full session

Session thumbnail

Heart failure pharmacology

The Event

Event poster

ESC Congress 2022

28 August 2022 15:15 CET

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Presentation

Audience Q&A

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources